News
SNNAQ
0.0001
NaN%
--
Weekly Report: what happened at SNNAQ last week (0223-0227)?
Weekly Report · 4d ago
Weekly Report: what happened at SNNAQ last week (0216-0220)?
Weekly Report · 02/23 10:36
Weekly Report: what happened at SNNAQ last week (0209-0213)?
Weekly Report · 02/16 10:36
Weekly Report: what happened at SNNAQ last week (0202-0206)?
Weekly Report · 02/09 10:38
Weekly Report: what happened at SNNAQ last week (0126-0130)?
Weekly Report · 02/02 10:38
Weekly Report: what happened at SNNAQ last week (0119-0123)?
Weekly Report · 01/26 10:37
Weekly Report: what happened at SNNAQ last week (0112-0116)?
Weekly Report · 01/19 10:46
Weekly Report: what happened at SNNAQ last week (0105-0109)?
Weekly Report · 01/12 10:44
Weekly Report: what happened at SNNAQ last week (1229-0102)?
Weekly Report · 01/05 10:37
Weekly Report: what happened at SNNAQ last week (1222-1226)?
Weekly Report · 12/29/2025 10:36
Weekly Report: what happened at SNNAQ last week (1215-1219)?
Weekly Report · 12/22/2025 10:36
Weekly Report: what happened at SNNAQ last week (1208-1212)?
Weekly Report · 12/15/2025 10:44
Weekly Report: what happened at SNNAQ last week (1201-1205)?
Weekly Report · 12/08/2025 10:43
Weekly Report: what happened at SNNAQ last week (1124-1128)?
Weekly Report · 12/01/2025 10:37
Weekly Report: what happened at SNNAQ last week (1117-1121)?
Weekly Report · 11/24/2025 10:43
Weekly Report: what happened at SNNAQ last week (1110-1114)?
Weekly Report · 11/17/2025 10:44
Weekly Report: what happened at SNNAQ last week (1103-1107)?
Weekly Report · 11/10/2025 10:41
Weekly Report: what happened at SNNAQ last week (1027-1031)?
Weekly Report · 11/03/2025 10:41
Weekly Report: what happened at SNNAQ last week (1020-1024)?
Weekly Report · 10/27/2025 10:45
Weekly Report: what happened at SNNAQ last week (1013-1017)?
Weekly Report · 10/20/2025 10:40
More
Webull provides a variety of real-time SNNAQ stock news. You can receive the latest news about Sienna Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About SNNAQ
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on bringing scientific innovations to patients whose lives remain burdened by their disease. Its lead candidate from its platform, SNA-120, is an inhibitor of Tropomyosin receptor kinase A (TrkA) for the treatment of psoriasis, as well as the associated pruritus (itch). The Company's second product candidate, SNA-125, is a dual Janus kinase 3 (JAK3)/TrkA inhibitor for the treatment of atopic dermatitis, psoriasis and the associated pruritus. In addition, the Company also offers SNA-001, a silver photo particle technology derived from its Topical Photoparticle Therapy platform.